Giá Cloudbreak Pharma Inc (02592.HK)

Cloudbreak Pharma, Inc. is an investment holding company, which engages in the research and development of therapeutic biologics. The company is headquartered in Irvine, California and currently employs 60 full-time employees. The company went IPO on 2025-07-03. The firm is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The firm has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.